Rare diseases specialist Swedish Orphan Biovitrum has appointed Anne Marie de Jonge Schuermans as head of its new Technical Operations organization, bringing together Sobi’s manufacturing operations/biological development and supply, quality, supply chain, procurement and environment and safety operations.
Ms de Jonge Schuermans will join on October 1, 2018, and be part of Sobi’s Executive Committee. She joins Sobi from Biogen (Nasdaq: BIIB) where she served as vice president for global supply chain operations and strategic partnerships and as an executive board member of Biogen International GmbH.
Ms de Jonge Schuermans brings more than 15 years of experience in the healthcare industry from Biogen, Stryker and Novartis. She has a track record of putting processes and systems in place, and of driving transformation in cross-functional and cross-cultural settings.
Ms de Jonge Schuermans says: “Sobi has unique capabilities, a heritage in biologics manufacturing, development and supply, and a very exciting future within the rare disease space. I look forward to working with the teams to develop an effective and agile organization set for growth.”
Source: The Pharma Letter
The United Arab Emirates (UAE) Ministry of Health and Prevention (MoHAP) has established a partnership with Novo Nordisk Pharma Gulf focusing on the creation of a national scientific guide for obesity management and weight control. The collaboration also aims to enhance public awareness of cardiovascular diseases and their complications.
Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in obesity. Under the deal, the companies will use Haya’s proprietary regulatory genome discovery platform to identify and validate long non-coding RNA (lncRNA) targets for developing potential treatments for obesity and related metabolic disorders.
The sale includes custom formulation and contract manufacturing capabilities for the nutrition market from the production facilities in New Jersey and Utah in the United States, and Tamaulipas, Mexico. Financial terms of the transaction were not disclosed.
